Conclusions
Many of the currently used tests for gestational disease provide only an estimation of risk as many mothers and foetuses never actually have or will ever develop the disease. Hence, it is vital to develop new prenatal screening tests that are more reliable and specific. We believe peptide markers may be able to fill this niche, however, ideally they should be unique to the condition and specific to a stage of the disease. It is clear that while peptides are very promising candidates, there is still much to be learnt. At present, not all markers are unique to any one particular condition and no consensus has yet been reached in any study undertaken. The issues are complex and it is hoped that proteomics/peptidomics will be able to compliment the vast amount of knowledge already gained from genomic and bioinformatic studies. Whereby, we will learn fresh data about the way placental markers are expressed, processed, post-translationally modified, secreted and metabolised in each of the different gestational diseases. It is anticipated that this will pave the way forward for the identification of specific targets for the design of robust, rapid and clinic friendly diagnostic assays. And, finally that some of these markers may see applications in therapeutic intervention.
Keywords
- Down Syndrome
- Maternal Serum
- Prenatal Screening
- Foetal Growth Retardation
- Eosinophil Major Basic Protein
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Andrews, W.W., Hauth, J.C., and Goldenberg, R.L., 2000, Infection and preterm birth. Am. J. Perinatol. 17:357–365.
Arnay, E., and Hill, D.J., 1998, Fibroblast growth factor-2 and fibroblast growth factor receptor-1 mRNA expression and peptide localization in placenta from normal and diabetic pregnancies. Placenta. 19:133–142.
Barker, D.J.P., 1989, Rise and fall of Western diseases. Nature. 338:371–372.
Berry, E., Aitken, D.A., Crossley, J.A., Macri, J.N., and Connor, J.M., 1997, Screening for Down’s syndrome: changes in marker levels and detection rates between first and second trimesters. Br. J. Obstet. Gynaecol. 104:811–817.
Bogart, M.H., Pandian, M.R., and Jones, O.W., 1987, Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat. Diagn. 7:623–30.
Boguski, M.S., 1995, The turning point in genome research. Trends in Biochemical Sciences. 20:295–6.
Brock, D.J., Bolton, A.E., and Monaghan, J.M., 1973, Prenatal diagnosis of anencephaly through maternal serum-alphafetoprotein measurement. Lancet. 2(7835):923–924.
Brock, D.J., and Sutcliffe, R.G., 1972, Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet. 2(7770):197–199.
Campbell, E.A., Linton, E.A., Wolfe, C.D., Scraggs, P.R., Jones, M.T., and Lowry, P.J., 1987, Plasma corticotrophin-releasing hormone concentrations during pregnancy and parturition. Journal of Clinical Endocrinology and Metabolism. 64:1054–1059
Cuckle, H.S., Wald, N.J., and Lindenbaum, R.H., 1984, Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet. 1(8383):926–929.
Cuckle, H.S., Wald, N.J., and Thompson, S.G., 1987, Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein level. Br. J. Obstet. Gynaecol. 94:387–402.
Cummins, J.M., 2002, The role of maternal mitochondria during oogenesis, fertilization and embryogenesis. Reprod. Biomed. Online. 4:176–182.
Elegbe, R.A., Pattillo, R.A., Hussa, R.O., Hoffmann, R.G., Damole, I.O., and Finlayson, W.E., 1984, Alpha subunit and human chorionic gonadotropin in normal pregnancy and gestational trophoblastic disease. Obstetrics and Gynecology. 63:335–337.
Fiehn, O., 2002, Metabolomics—the link between genotypes and phenotypes. Plant Mol. Biol. 48:155–171.
Govorun, V.M., Archakov, A.I., 2002, Proteomic technologies in modern biomedical science. Biochemistry (Mosc). 67:1109–1123.
Hill, D.J., Petrik, J., and Arany, E., 1998, Growth factors and the regulation of fetal growth. Diabetes Care. 21(Suppl 2):B60–69.
Hoang, V.M., Foulk, R., Clauser, K., Burlingame, A., Gibson, B.W., and Fisher, S.J., 2001, Functional proteomics: examining the effects of hypoxia on the cytotrophoblast protein repertoire. Biochemistry. 40:4077–4086.
Hook, E.B., 1981, Rates of chromosome abnormalities at different maternal ages. Obstet. Gynecol. 58:282–285.
Ishimura, R., Yoshida, K., Kimura, H., Dohmae, N., Takio, K., Ogawa, T., Tanaka, S., and Shiota, K., 2001, Stage-specific modification of G protein beta subunits in rat placenta. Mol. Cell. Endocrinol. 174:77–89.
Jaffe, R., Jauniaux, E., and Hustin, J., 1997, Maternal circulation in the first-trimester human placenta-myth or reality? Am. J. Obstet. Gynecol. 176:695–705.
John, M., Rajalekshmy, T.N., Nair, M.B., Augustine, J., Schultz, G., Nair, M.K., and Balaram, P., 1997, Expression of epidermal growth factor in gestational trophoblastic disease (GTD). Journal of Experimental Clinical Cancer Research 16:129–134.
Jurgens, M., and Schrader, M., 2002, Peptidomic approaches in proteomic research. Curr. Opin. Mol. Ther. 4:236–241.
Kennedy, S., 2001, Proteomic profiling from human samples: the body fluid alternative. Toxicol. Lett. 120:379–384.
Lin, T.M., Halbert, S.P., and Kiefer, D., 1976, Quantitative analysis of pregnancy-associated plasma proteins in human placenta. J. Clin. Invest. 57:466–472.
Lopez-Otin, C., and Overall, C.M. 2002, Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell. Biol. 3:509–519.
Luscombe, N.M., Greenbaum, D., and Gerstein, M., 2001, What is bioinformatics? A proposed definition and overview of the field. Methods of Information in Medicine. 40: 346–358.
Mauldin, J.G., and Newman, R.B., 2001, Preterm birth risk assessment. Semin. Perinatol. 25:215–222.
McCormick, M.C., 1985, The contribution of low birth weight to infant mortality and childhood morbidity. New England Journal of Medicine. 312:82–90.
McLean, M., and Smith, R., 1999, Corticotropin-releasing hormone in human pregnancy and parturition Trends in Endocrinology and Metabolism. 10:174–178.
Merkatz, I.R., Nitowsky, H.M., Macri, J.N., and Johnson, W.E., 1984, An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am. J. Obstet. Gynecol. 148:886–894.
Mikkelsen, M., Poulsen, H., and Nielsen, K.G., 1990, Incidence, survival, and mortality in Down syndrome in Denmark. Am. J. Med. Genet. Suppl. 7:75–78.
National Institutes of Health, 2000, Working group report on high blood pressure in pregnancy. NIH publication, No. 00-3029 July.
Nicolaides, K., Brizot Mde, L., Patel, F., and Snijders, R., 1994, Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10–13 weeks’ gestation. Lancet. 344(8920):435–439.
Overgaard, M.T., Sorensen, E.S., Stachowiak, D., Boldt, H.B., Kristensen, L., Sottrup-Jensen, L., and Oxvig, C., 2003, Complex of Pregnancy-associated Plasma Protein-A and the Proform of Eosinophil Major Basic Protein. J. Biol. Chem. 278:2106–2117.
Palomaki, G.E., Knight, G.J., McCarthy, J.E., Haddow, J.E., and Donhowe, J.M., 1997, Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am. J. Obstet. Gynecol. 176:1046–1051.
Page, N.M., 2002, The endocrinology of pre-eclampsia. Clin. Endocrinol. (Oxf). 57:413–23.
Page, N.M., Butlin, D.J., Lomthaisong, K., and Lowry, P.J., 2001, The characterization of pregnancy associated plasma protein-E and the identification of an alternative splice variant. Placenta. 22:681–687.
Page, N., Butlin, D., Manyonda, I., and Lowry, P., 2000, The development of a genetic profile of placental gene expression during the first trimester of pregnancy: a potential tool for identifying novel secreted markers. Fetal Diagn Ther. 15:237–245.
Page, N.M., Woods, R.J., Gardiner, S.M., Lomthaisong, K., Gladwell, R.T., Butlin, D.J., Manyonda, I.T., and Lowry, P.J., 2000, Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature. 405:797–800.
Page, N.M., Kemp, C.F., Butlin, D.J., and Lowry, P.J., 2002, Placental peptides as markers of gestational disease. Reproduction. 123:487–495.
Pardi, G., Marconi, A.M., Cetin, I., 2002, Placental-fetal interrelationship in IUGR fetuses — a review. Placenta. 23SupplA:S136–141.
Pellois, J.P., Zhou, X., Srivannavit, O., Zhou, T., Gulari, E., and Gao, X., 2002, Individually addressable parallel peptide synthesis on microchips. Nat. Biotechnol. 20:922–6.
Persson, B., Westgren, M., Celsi, G., Nord, E., and Ortqvist, E., 1999, Leptin concentrations in cord blood in normal newborn infants and offspring of diabetic mothers. Hormone Metabolism Research 31:467–771.
Petricoin, E.F., and Liotta, L.A., 2002, Proteomic analysis at the bedside: early detection of cancer. Trends Biotechnol. 20(12 Suppl):S30–34.
Rabilloud, T., Kieffer, S., Procaccio, V., Louwagie, M., Courchesne, P.L., Patterson, S.D., Martinez, P., Garin, J., and Lunardi, J., 1998, Two-dimensional electrophoresis of human placental mitochondria and protein identification by mass spectrometry: toward a human mitochondrial proteome. Electrophoresis. 19:1006–1014.
Regnault, T.R., Galan, H.L., Parker, T.A., and Anthony, R.V., 2002, Placental development in normal and compromised pregnancies — a review. Placenta. 23SupplA:S119–129.
Romero, R., Kuivaniemi, H., and Tromp, G., 2002, Functional genomics and proteomics in term and preterm parturition. J. Clin. Endocrinol. Metab. 87:2431–2434.
Sawicki, G., Dakour, J., and Morrish, D.W., 2002, Proteomics of neurokinin B in the placenta demonstrates novel actions in suppressing placental antioxidant defenses. Proceedings of the Swiss Proteomics Society. In Congress Applied Proteomics. Editors: (Palagi, P.M., Quadroni, M., Rossier, J.S. Sanchez, J.C., and Stocklin, R.), FontisMedia SA, Lausanne, Switzerland, pp.102–104.
Schulz-Knappe, P., Schrader, M., Standker, L., Richter, R., Hess, R., Jurgens, M., and Forssmann, W.G., 1997, Peptide bank generated by large-scale preparation of circulating human peptides. J. Chromatogr. A. 776:125–132.
Schulz-Knappe, P., Zucht, H.D., Heine, G., Jurgens, M., Hess, R., and Schrader, M., 2001, Peptidomics: the comprehensive analysis of peptides in complex biological mixtures. Comb. Chem. High. Throughput Screen. 4:207–217.
Scott, F., Peters, H., Boogert, T., Robertson, R., Anderson, J., McLennan, A., Kesby, G., and Edelman, D., 2002, The loss rates for invasive prenatal testing in a specialised obstetric ultrasound practice. Aust. N. Z. J. Obstet. Gynaecol. 42:55–58.
Spencer, K., Souter, V., Tul, N., Snijders, R., and Nicolaides, K.H., 1999, A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet. Gynecol. 13:231–237.
Tamas, G., and Kerenyi, Z., 2001, Gestational diabetes: current aspects on pathogenesis and treatment. Exp. Clin. Endocrinol. Diabetes. 109Suppl2:S400–411.
Tongsong, T., Wanapirak, C., Kunavikatikul, C., Sirirchotiyakul, S., Piyamongkol, W., and Chanprapaph, P., 2000, Cordocentesis at 16–24 weeks of gestation: experience of 1,320 cases. Prenat. Diagn. 20:224–228.
Vihinen, M., 2001, Bioinformatics in proteomics. Biomol. Eng. 18:241–248.
Wahlstrom, T., Stenman, U.H., Lundqvist, C., Tanner, P., Schroder, J., and Seppala, M., 1981, The use of monoclonal antibodies against human chorionic gonadotropin for immunoperoxidase staining of normal placenta, pituitary gland, and pituitary adenomas. J. Histochem. Cytochem. 29:864–865.
Wald, N.J., Cuckle, H., Brock, J.H., Peto, R., Polani, P.E., and Woodford, F.P., 1977, Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet. 1(8026):1323–1332.
Wald, N.J., Densem, J.W., Smith, D.,, G.G., 1994, Four-marker serum screening for Down’s syndrome. Prenat. Diagn. 14:707–716.
Wang, Y., and Walsh, S.W., 1998, Placental mitochondria as a source of oxidative stress in pre-eclampsia. Placenta. 19:581–586.
Yagami, Y., and Ito, Y., 1965, Immunological assay of human serum chorionic gonadotrophin in normal and abnormal pregnancy. J. Jpn. Obstet. Gynecol. Soc. 12:82–88.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Page, N.M. (2004). Proteomics and Peptidomics of Gestational Disease. In: Hondermarck, H. (eds) Proteomics: Biomedical and Pharmaceutical Applications. Springer, Dordrecht. https://doi.org/10.1007/1-4020-2323-5_8
Download citation
DOI: https://doi.org/10.1007/1-4020-2323-5_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-2322-4
Online ISBN: 978-1-4020-2323-1
eBook Packages: Springer Book Archive